Article

Adverse effects of antidepressant use in pregnancy: an evaluation of fetal growth and preterm birth

The Motherisk Program, The Hospital for Sick Children, Toronto, Canada.
Depression and Anxiety (Impact Factor: 4.29). 01/2010; 27(1):35-8. DOI: 10.1002/da.20598
Source: PubMed

ABSTRACT To compare the rates of low birth weight, preterm delivery and small for gestational age (SGA), in pregnancy outcomes among women who were exposed and nonexposed to antidepressants during pregnancy.
At The Motherisk Program, we analyzed pregnancy outcomes of 1,243 women in our database who took various antidepressants during their pregnancy. Nine hundred and twenty-eight of these women and 928 nonexposed women who delivered a live born infant were matched for age, (+/-2 years), smoking and alcohol use and specific pregnancy outcomes were compared between the two groups.
There were 82 (8.8%) preterm deliveries in the antidepressant group and 50 (5.4%) in the comparison group. OR: 1.7 (95% CI: 1.18-2.45). There were 89 (9.6%) in the antidepressant group and 76 (8.2%) in the comparison group who delivered babies evaluated as SGA; OR: 1.19 (95% CI: 0.86-1.64). The mean birth weight in the antidepressant group was 3,449+/-591 g and 3,455+/-515 g in the comparison group (P=.8).
The use of antidepressants in pregnancy appears to be associated with a small, but statistically significant increased rate in the incidence of preterm births, confirming results from several other studies. It is difficult to ascertain whether this small increased rate of preterm births is confounded by depression, antidepressants, or both. However, we did not find a statistically significant difference in the incidence of SGA or lower birth weight. This information adds to limited data available in the literature regarding these outcomes following the use of antidepressants in pregnancy.

1 Follower
 · 
110 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: To date, many studies have been published regarding the safety of antidepressant use in pregnancy. However, most have been regarding a possible association with major malformations and there have been relatively few studies that have examined other infant outcomes specifically.
    The Israel journal of psychiatry and related sciences 01/2014; 51(2):94-104. · 0.72 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: RationaleKnowledge transfer and translation (KT) has become an important component in health care systems worldwide. Antidepressant use in pregnancy has become a controversial subject for a number of reasons, including differing interpretations of study results.Methods Selected key articles were indentified and retrieved from the literature. Relevant information was extracted and synthesized into themes, addressing each of the stated objectives.Objectives(1) To determine how knowledge regarding the safety/risk of antidepressant use in pregnancy is created; (2) to describe different research models and statistical analyses that have been used, so as to critically evaluate the results; and (3) to identify how this information is currently disseminated.ResultsAll of the methods used for examining the safety of antidepressants in pregnancy have some deficiencies in study design and analysis, thus reinforcing the need for accurate interpretations when discussing results. In addition, dissemination in both the scientific and lay press has been selective and therefore potentially biased.Conclusion It is critical, starting with the creators of knowledge, through to the recipients that discrepancies are resolved, as lack of clarity may impede the transfer of unambiguous evidence-based information from health care providers to patients, thus impacting decision making. For example, by implementing improved (KT) strategies, a pregnant, depressed woman, will be empowered to make a rational evidence-based decision regarding whether or not she should take an antidepressant during pregnancy.
    Journal of Evaluation in Clinical Practice 04/2015; DOI:10.1111/jep.12338 · 1.58 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Prenatal depression can negatively affect the physical and mental health of both mother and fetus. The aim of this study was to determine the effectiveness of yoga as an intervention in the management of prenatal depression.MethodsA systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted by searching PubMed, Embase, the Cochrane Library and PsycINFO from all retrieved articles describing such trials up to July 2014.ResultsSix RCTs were identified in the systematic search. The sample consisted of 375 pregnant women, most of whom were between 20 and 40 years of age. The diagnoses of depression were determined by their scores on Structured Clinical Interview for DSM-IV and the Center for Epidemiological Studies Depression Scale. When compared with comparison groups (e.g., standard prenatal care, standard antenatal exercises, social support, etc.), the level of depression statistically significantly reduced in yoga groups (standardized mean difference [SMD], ¿0.59; 95% confidence interval [CI], ¿0.94 to ¿0.25; p¿=¿0.0007). One subgroup analysis revealed that both the levels of depressive symptoms in prenatally depressed women (SMD, ¿0.46; CI, ¿0.90 to ¿0.03; p¿=¿0.04) and non-depressed women (SMD, ¿0.87; CI, ¿1.22 to ¿0.52; p¿<¿0.00001) were statistically significantly lower in yoga group than that in control group. There were two kinds of yoga: the physical-exercise-based yoga and integrated yoga, which, besides physical exercises, included pranayama, meditation or deep relaxation. Therefore, the other subgroup analysis was conducted to estimate effects of the two kinds of yoga on prenatal depression. The results showed that the level of depression was significantly decreased in the integrated yoga group (SMD, ¿0.79; CI, ¿1.07 to ¿0.51; p¿<¿0.00001) but not significantly reduced in physical-exercise-based yoga group (SMD, ¿0.41; CI, ¿1.01 to ¿0.18; p¿=¿0.17).Conclusions Prenatal yoga intervention in pregnant women may be effective in partly reducing depressive symptoms.
    BMC Psychiatry 02/2015; 15(1):14. DOI:10.1186/s12888-015-0393-1 · 2.24 Impact Factor